In this study, we showed that LSD1 regulated AR activity in kidney cancer cells and demonstrated that pargyline, used as a LSD1 inhibitor, reduced the kidney cancer cell proliferation rate and metastatic ability. This evidence concerns the gene AR and kidney cancer.